National Library of Medicine NLM

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.
- Click on query # to add to strategy

Search	Most Recent Queries	Time	Result
#1	Search **succinyl prodrug**	14:00:13	21
#3	**Related Articles** for **PubMed** (Select **11606140**)	13:58:38	242

Clear History

L Number	Hits	Search Text	DB	Time stamp
1	26	(("4277466") or ("4296106") or ("4376765") or ("4388305") or ("4639456") or ("4671958") or ("4703107") or ("4719312") or ("4870162") or ("5024835") or ("5220001") or ("5599686") or ("5962216")).PN.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 15:20
2	13	(("4277466") or ("4296106") or ("4376765") or ("4388305") or ("4639456") or ("4671958") or ("4703107") or ("4719312") or ("4870162") or ("5024835") or ("5220001") or ("5599686") or ("5962216")).PN.	USPAT	2004/10/25 15:20
-	24278	hydrazide	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 13:37
-	123	hydrazide and dox	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/23 12:11
-	4424	hydrazide and top	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/23 12:12
-	48	(hydrazide and dox) and (hydrazide and top)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/23 12:12
-	733	succinyl and prodrug	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 13:51
-	552	(succinyl and prodrug) and peptide	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 13:51
-	694	succinyl same peptide	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 13:52
-	8	(succinyl same peptide) same prodrug	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 13:52
-	2	WO-9605863-$.did.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 13:52
-	0	WO-9605863-$.did. and succinyl	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 13:53
-	2	5962216.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 14:16
-	1	5962216.pn. and succinyl	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 15:01
-	0	09879442.did.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 15:01

-	0	09879442.an.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 15:18

L Number	Hits	Search Text	DB	Time stamp
1	26	(("4277466") or ("4296106") or ("4376765") or ("4388305") or ("4639456") or ("4671958") or ("4703107") or ("4719312") or ("4870162") or ("5024835") or ("5220001") or ("5599686") or ("5962216")).PN.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 15:20
2	13	(("4277466") or ("4296106") or ("4376765") or ("4388305") or ("4639456") or ("4671958") or ("4703107") or ("4719312") or ("4870162") or ("5024835") or ("5220001") or ("5599686") or ("5962216")).PN.	USPAT	2004/10/25 15:20
-	24278	hydrazide	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 13:37
-	123	hydrazide and dox	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/23 12:11
-	4424	hydrazide and top	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/23 12:12
-	48	(hydrazide and dox) and (hydrazide and top)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/23 12:12
-	733	succinyl and prodrug	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 13:51
-	552	(succinyl and prodrug) and peptide	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 13:51
-	694	succinyl same peptide	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 13:52
-	8	(succinyl same peptide) same prodrug	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 13:52
-	2	WO-9605863-$.did.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 13:52
-	0	WO-9605863-$.did. and succinyl	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 13:53
-	2	5962216.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 14:16
-	1	5962216.pn. and succinyl	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 15:01
-	0	09879442.did.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 15:01

-	0	09879442.an.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 15:18

L Number	Hits	Search Text	DB	Time stamp
-	24278	hydrazide	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 13:37
-	123	hydrazide and dox	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/23 12:11
-	4424	hydrazide and top	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/23 12:12
-	48	(hydrazide and dox) and (hydrazide and top)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/23 12:12
-	733	succinyl and prodrug	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 13:51
-	552	(succinyl and prodrug) and peptide	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 13:51
-	694	succinyl same peptide	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 13:52
-	8	(succinyl same peptide) same prodrug	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 13:52
-	2	WO-9605863-$.did.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 13:52
-	0	WO-9605863-$.did. and succinyl	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 13:53
-	2	5962216.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 14:16
-	1	5962216.pn. and succinyl	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 15:01
-	0	09879442.did.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 15:01
-	0	09879442.an.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 15:18
-	26	(("4277466") or ("4296106") or ("4376765") or ("4388305") or ("4639456") or ("4671958") or ("4703107") or ("4719312") or ("4870162") or ("5024835") or ("5220001") or ("5599686") or ("5962216")).PN.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 15:20

-	13	(("4277466") or ("4296106") or ("4376765") or ("4388305") or ("4639456") or ("4671958") or ("4703107") or ("4719312") or ("4870162") or ("5024835") or ("5220001") or ("5599686") or ("5962216")).PN.	USPAT	2004/10/25 15:20
-	2	("6372712").PN.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 17:30
-	1	(("6372712").PN.) and hydrazide	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/10/25 17:30

Google Web Images Groups News Froogle more »
succinyl use Search Advanced Search Preferences

Web

Results 1 - 10 of about 12,800 for succinyl use. (0.27 seconds)

The use of N-succinyl derivatives in the study of amino acids and ...
Biomed Mass Spectrom. 1976 Aug;3(4):191-5. The use of N-succinyl derivatives in the study of amino acids and peptides by mass spectrometry. ...
www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve& db=PubMed&list_uids=963278&dopt=Abstract - Similar pages

Bacterial distribution of the use of succinyl and acetyl blocking ...
J Bacteriol. 1970 Jan;101(1):323-4. Bacterial distribution of the use of succinyl and acetyl blocking groups in diaminopimelic acid biosynthesis. ...
www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve& db=PubMed&list_uids=5411754&dopt=Abstract - Similar pages
[More results from www.ncbi.nlm.nih.gov]

[PDF] Chemistr y 527 Answers to Pr oblem Set 10
File Format: PDF/Adobe Acrobat - View as HTML
... Problem Set 10 due May 11, 2004 a. Write down the names and structures of each intermediate between aspartate and O-succinyl- homoserine. Use the information ...
www.udel.edu/chem/mueller/pages/ chem527/problem%20sets/527ans1004.pdf - Similar pages

[PDF] Succinyl-CoA : 3-ketoacid CoA transferase (SCOT) deficiency
File Format: PDF/Adobe Acrobat
... T, Kondo N. Succinyl-CoA:3-ketoacid coenzyme A transferase (SCOT): development of an antibody to human SCOT and diagnostic use in hereditary SCOT deficiency. ...
www.orpha.net/data/patho/GB/uk-scot.pdf - Similar pages

[PDF] Succinyl-CoA synthetase and succinyl-CoA:3-oxoacid CoA transferase
File Format: PDF/Adobe Acrobat - View as HTML
... of pig heart GTP-specific SCS were soaked with the nonhydrolyzable succinyl-CoA analogue ... Use of the Advanced Photon Source was supported by the US Department of ...
www.aps.anl.gov/xfd/communicator/user2000/fraserm1.pdf - Similar pages

ChemFinder.Com
... Search here for free. For professional searching, use ChemINDEX. (Hydroxymethylphenyl) succinyl-CoA Synonyms: (Hydroxymethylphenyl)succinyl-CoA; ...
chemfinder.cambridgesoft.com/ result.asp?mol_rel_id=CS62044 - 21k - Cached - Similar pages

Bacterial Distribution of the Use of Succinyl and Acetyl Blocking ...
... 1970 January; 101 (1): 323 324 Bacterial Distribution of the Use of Succinyl and Acetyl Blocking Groups in Diaminopimelic Acid Biosynthesis. ...
www.pubmedcentral.nih.gov/ articlerender.fcgi?artid=250485 - Similar pages

BIOCHEMISTRY II
... d) plants use glutamic acid coupled to tRNA as a starting substrate. e) animals use glycine and succinyl-CoA as starting substrates. 10. ...
www.ksu.edu/bchem/courses/ BIOCH765/LD/old_exams/samplex88.htm - 17k - Cached - Similar pages

Fraser - Division of Biochemistry - About - Dept of Bio Sci ...
... citric acid cycle, SCS catalyzes the reaction that uses a molecule of succinyl-CoA and ... some forms of SCS can use either ADP or GDP while other forms can use ...
www.bio.ucalgary.ca/divisions/biochem/fraser.html - 31k - Oct 24, 2004 - Cached - Similar pages

Avanti Polar Lipids
... "); // global background. Ask An Avanti Scientist Product Number: Product Name:

16:0 **Succinyl** PE. **Use** Of This Product: Research Pharmaceutical Analytical Other. ...
www.avantilipids.com/ProductQuestion.asp?Number=870225 - 29k - Cached - Similar pages

Gooooooooogle ▶
Result Page: 1 2 3 4 5 6 7 8 9 10 **Next**

Google Web Images Groups News Froogle more »

succinyl hydrolysis Search Advanced Search Preferences

Web

Results **1** - **10** of about **5,210** for **succinyl hydrolysis**. (**0.23** seconds)

Succinyl CoA - encyclopedia article about **Succinyl** CoA. Free ...
... Types. In a **hydrolysis** reaction that involves breaking an ester link, one **hydrolysis** product contains a hydroxyl ... release of coenzyme A by **succinyl**-CoA synthetase ...
encyclopedia.thefreedictionary.com/Succinyl%20CoA - 23k - Cached - Similar pages

Hydrolysis of **succinyl**-trialanine p-nitroanilide by two enzymes ...
1983 Oct 15;226(2):629-35. **Hydrolysis** of **succinyl**-trialanine p-nitroanilide by two enzymes associated with human high-density lipoproteins. ...
www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve& db=PubMed&list_uids=6357093&dopt=Abstract - Similar pages

[Solid-state enzymatic reactions. II. Chymotrypsin **hydrolysis** of N ...
... II. Chymotrypsin **hydrolysis** of N-**succinyl**-L-phenylalanine n-nitroanilide] [Article in Russian] Khurgin Iul, Medvedeva PV, Rosliakov Vla. ...
www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve& db=PubMed&list_uids=588602&dopt=Abstract - Similar pages
[More results from www.ncbi.nlm.nih.gov]

Adrenocorticotropins (ACTH). XX. **SUCCINYL**-ADRENOCORTICOTROPIN AND ...
Institution: Google Indexer Sign In as Member/Non-Member. PDF Version Automatic download [Begin manual download] Downloading the PDF version of: J. Biol. Chem. ...
www.jbc.org/cgi/framedreprint/235/9/2638 - Similar pages

Citric Acid Cycle Reactions
... dehydrogenase complex. Reaction 6 Chime in new window. Reaction 7: **Hydrolysis** of **Succinyl** CoA; Synthesis of ATP. The **hydrolysis** of ...
www.elmhurst.edu/~chm/vchembook/611citricrx.html - 20k - Cached - Similar pages

KE0026 Biochemistry Exercises
... by **succinyl** CoA synthetase. The DG°' for **hydrolysis** of **succinyl** CoA is about -8 kcal/mol, comparable with that of ATP (or GTP). ...
xray.bmc.uu.se/Courses/Bke1/Exercises/ Exercise_answers/Exercise_answers9.html - 10k - Cached - Similar pages

NiceSite View of PROSITE: PDOC00335 (documentation file)
... [3] is a bacterial enzyme that during aerobic metabolism functions in the citric acid cycle, coupling the **hydrolysis** of **succinyl**-CoA to the synthesis of ATP. ...
www.expasy.org/cgi-bin/nicedoc.pl?PDOC00335 - 13k - Cached - Similar pages

Search Results
... During aerobic metabolism it functions in the citric acid cycle, coupling the **hydrolysis** of **succinyl**-CoA to the synthesis of ATP & thus represents an important ...
www.stdgen.lanl.gov/cgi-bin/gene_ id_search.cgi?dbname=ngon&gene_id=NG0912 - 17k - Cached - Similar pages

Citric Acid Cycle
... GDP. See Fig. 19-15. **Hydrolysis** of **succinyl**-CoA -7.7 kCal/mol, -32.6 kJ/mol. Synthesis of GTP -7.4 kCal/mol - efficient! One acetyl ...
opbs.okstate.edu/~leach/ Bioch5853/Text/Notes/Ch19V&V.html - 17k - Cached - Similar pages

Krebs
... Catalyzed by Succinic Thiokinase (**Succinyl**-CoA Synthetase). The **hydrolysis** of the thiolester of **Succinyl**- CoA yields the energy needed to produce GTP: ...
www.nova.edu/~edwardok/Krebs.htm - 25k - Cached - Similar pages

Goooooooooogle ▶

Result Page: 1 2 3 4 5 6 7 8 9 10 **Next**

```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssspta1653adk

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * *
* *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  Jul 12   BEILSTEIN enhanced with new display and select
options,
                   resulting in a closer connection to BABS
 NEWS  4  AUG 02   IFIPAT/IFIUDB/IFICDB reloaded with new search and
display
                   fields
 NEWS  5  AUG 02   CAplus and CA patent records enhanced with European
and Japan
                   Patent Office Classifications
 NEWS  6  AUG 02   The Analysis Edition of STN Express with Discover!
                   (Version 7.01 for Windows) now available
 NEWS  7  AUG 27   BIOCOMMERCE: Changes and enhancements to content
coverage
 NEWS  8  AUG 27   BIOTECHABS/BIOTECHDS: Two new display fields added
for legal
                   status data from INPADOC
 NEWS  9  SEP 01   INPADOC: New family current-awareness alert (SDI)
available
 NEWS 10  SEP 01   New pricing for the Save Answers for SciFinder
Wizard within
                   STN Express with Discover!
 NEWS 11  SEP 01   New display format, HITSTR, available in
WPIDS/WPINDEX/WPIX
 NEWS 12  SEP 27   STANDARDS will no longer be available on STN
 NEWS 13  SEP 27   SWETSCAN will no longer be available on STN

 NEWS EXPRESS  JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to
STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to
scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * *
* *

FILE 'HOME' ENTERED AT 12:28:11 ON 25 OCT 2004

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE
TOTAL
                                                      ENTRY
SESSION
FULL ESTIMATED COST                                    0.21
0.21

FILE 'REGISTRY' ENTERED AT 12:28:15 ON 25 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   24 OCT 2004  HIGHEST RN 768347-62-2
DICTIONARY FILE UPDATES:  24 OCT 2004  HIGHEST RN 768347-62-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for
details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading H:\STN queries\09879442e.str
```



```
chain nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20
21  22  23  24  25  26  27  28  29
chain bonds :
1-3  1-2  3-4  4-5  5-6  5-7  6-8  6-17  9-14  9-10  9-18  10-11  11-
12  11-13  14-15  15-16  15-20  17-18  18-19  20-21  21-22  22-23
23-24  23-25  25-26  26-27  27-28  27-29
exact/norm bonds :
1-2  3-4  4-5  5-7  6-17  9-14  14-15  15-16  17-18  18-19  21-22
22-23  23-24  27-28  27-29
exact bonds :
1-3  5-6  6-8  9-10  9-18  10-11  11-12  11-13  15-20  20-21  23-25
25-26  26-27


Match level :
1:CLASS  2:CLASS  3:CLASS  4:CLASS  5:CLASS  6:CLASS  7:CLASS
8:CLASS  9:CLASS  10:CLASS  11:CLASS  12:CLASS  13:CLASS  14:CLASS
15:CLASS  16:CLASS  17:CLASS  18:CLASS  19:CLASS  20:CLASS  21:CLASS
22:CLASS  23:CLASS  24:CLASS  25:CLASS  26:CLASS  27:CLASS  28:CLASS
29:CLASS



L1      STRUCTURE UPLOADED

=>
Uploading H:\STN queries\09879442d.str
```



```
chain nodes :
19  20  21  22  23  24  31  32  33  34  35  36  37  38  39  40  41
42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58
59  60  61
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  25  26
27  28  29  30
chain bonds :
6-21  7-19  10-20  11-61  14-23  16-56  16-57  18-24  21-22  24-28
25-32  26-33  30-31  31-34  34-35  34-36  36-37  37-38  38-39  38-40
39-41  39-50  42-47  42-43  42-51  43-44  44-45  44-46  47-48  48-49
48-53  50-51  51-52  53-54  54-55  56-58  56-59  59-60
ring bonds :
1-2  1-6  2-3  3-4  4-5  4-7  5-6  5-10  7-8  8-9  8-11  9-10  9-14
11-12  12-13  12-15  13-14  13-18  15-16  16-17  17-18  25-26  25-30
```

```
26-27  27-28  28-29  29-30
exact/norm bonds :
4-7  5-10  6-21  7-8  7-19  9-10  10-20  11-61  12-15  13-18  14-23
15-16  16-17  16-57  17-18  18-24  21-22  24-28  25-26  25-30  25-32
26-27  27-28  28-29  29-30  30-31  31-34  34-35  36-37  37-38  38-40
39-50  42-47  47-48  48-49  50-51  51-52  54-55  56-58  59-60
exact bonds :
16-56  26-33  34-36  38-39  39-41  42-43  42-51  43-44  44-45  44-46
48-53  53-54  56-59
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  8-9  8-11  9-14  11-12  12-13  13-14


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom
9:Atom  10:Atom  11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom
17:Atom  18:Atom  19:CLASS  20:CLASS  21:CLASS  22:CLASS  23:CLASS
24:CLASS  25:Atom  26:Atom  27:Atom  28:Atom  29:Atom  30:Atom
31:CLASS  32:CLASS  33:CLASS  34:CLASS  35:CLASS  36:CLASS  37:CLASS
38:CLASS  39:CLASS  40:CLASS  41:CLASS  42:CLASS  43:CLASS  44:CLASS
45:CLASS  46:CLASS  47:CLASS  48:CLASS  49:CLASS  50:CLASS  51:CLASS
52:CLASS  53:CLASS  54:CLASS  55:CLASS  56:CLASS  57:CLASS  58:CLASS
59:CLASS  60:CLASS  61:CLASS



L2      STRUCTURE UPLOADED

=> s l1 sam
SAMPLE SEARCH INITIATED 12:29:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  10098 TO ITERATE

  9.9% PROCESSED     1000 ITERATIONS                                  0
ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       195939 TO   207981
PROJECTED ANSWERS:               0 TO        0

L3            0 SEA SSS SAM L1

=> s l1 fam
SAMPLE SEARCH INITIATED 12:29:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     148 TO ITERATE

100.0% PROCESSED     148 ITERATIONS                                  0
ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         2231 TO     3689
PROJECTED ANSWERS:               0 TO        0

L4            0 SEA FAM SAM L1

=> s l1 ful
FULL SEARCH INITIATED 12:29:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 203961 TO ITERATE

100.0% PROCESSED  203961 ITERATIONS                                17
ANSWERS
SEARCH TIME: 00.00.05

L5           17 SEA SSS FUL L1

=> s l2 sam
SAMPLE SEARCH INITIATED 12:29:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      6 TO ITERATE

100.0% PROCESSED        6 ITERATIONS                               1
ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:             6 TO       266
PROJECTED ANSWERS:                1 TO        80

L6            1 SEA SSS SAM L2

=> s l2 fam
SAMPLE SEARCH INITIATED 12:29:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      2 TO ITERATE

100.0% PROCESSED        2 ITERATIONS                               0
ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:             2 TO       124
PROJECTED ANSWERS:                0 TO         0

L7            0 SEA FAM SAM L2

=> s l2 ful
FULL SEARCH INITIATED 12:29:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    125 TO ITERATE

100.0% PROCESSED     125 ITERATIONS                               11
ANSWERS
SEARCH TIME: 00.00.01

L8           11 SEA SSS FUL L2

=> l5 not l8
L9           13 L5 NOT L8

=> l5 and l8

L10           4 L5 AND L8

=> l8 not l10
L11           7 L8 NOT L10

=> l9 or l10 or l11
L12          24 L9 OR L10 OR L11

=> d l12 1-24 ide ibib

L12  ANSWER 1 OF 24  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   501366-48-9  REGISTRY
CN   L-Phenylalaninamide, L-α-aspartyl-L-leucyl-L-α-aspartyl-3-
     amino-2-hydroxypentanoyl-L-leucyl-L-leucyl- (9CI)  (CA INDEX
NAME)
FS   PROTEIN SEQUENCE; STEREOSEARCH
MF   C40 H64 N8 O12
SR   CA
LC   STN Files:   CA, CAPLUS, CASREACT
DT.CA  CAplus document type:  Journal
RL.NP  Roles from non-patents:  BIOL (Biological study); CMBI
(Combinatorial
       study); PREP (Preparation)

Absolute stereochemistry.
```



```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             1 REFERENCES IN FILE CA (1907 TO DATE)
             1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE  1

ACCESSION NUMBER:         138:238425  CA Full-text
TITLE:                    Solid-Phase Combinatorial Library of
Norstatine-Type
                          Isosters by the Nitroaldol Reaction
AUTHOR(S):                Willert, Marianne; Benito, Juan M.; Meldal,
Morten
CORPORATE SOURCE:         Department of Chemistry, Carlsberg
Laboratory, Valby,
                          DK-2500, Den.

SOURCE:                   Journal of Combinatorial Chemistry (2003),
5(2),
                          91-101
                          CODEN: JCCHFF; ISSN: 1520-4766
PUBLISHER:                American Chemical Society
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
REFERENCE COUNT:          39    THERE ARE 39 CITED REFERENCES
AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

L12  ANSWER 2 OF 24  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   477328-64-6  REGISTRY
CN   Leucinamide, N-(3-carboxy-1-oxopropyl)-β-alanylleucylalanyl-N-
[6-[[2-
     [[[2-[[(1S)-1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-
(methoxycarbonyl)-7-
     methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-
     benzofuranyl]amino]carbonyl]-5-benzofuranyl]amino]-6-oxohexyl]-
(9CI)  (CA
     INDEX NAME)
FS   PROTEIN SEQUENCE; STEREOSEARCH
MF   C60 H72 Cl N9 O15
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
DT.CA  CAplus document type:  Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP
(Preparation); USES
       (Uses)

Absolute stereochemistry.
```






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 138:4470 CA Full-text
TITLE: Preparation of duocarmycin analogs as potent cytotoxins
INVENTOR(S): Ng, Howard P.; McGee, Danny P. C.; Wu, Guoxian; Li, Zhihong; Gangwar, Sanjeev; Saunders, Oliver L.; Martichonok, Valeri; Astafieva, Irina; Moore, Jimmie; Yarranton, Geoffrey Thomas; King, David J.; Boyd, Sharon; Lobl, Thomas J.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., A Wholly Owned Subsidiary of Corixa Corporation, USA
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096910	A1	20021205	WO 2002-US17210	20020531

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003050331	A1	20030313	US 2002-160972	20020531
US 2003064984	A1	20030403	US 2002-161234	20020531
US 2003073852	A1	20030417	US 2002-161233	20020531
NZ 529788	A	20031219	NZ 2002-529788	20020531
EP 1434778	A1	20040707	EP 2002-731994	20020531

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:

US 2001-295196P	20010531
US 2001-295259P	20010531
US 2001-295342P	20010531
US 2001-304908P	20010711
WO 2002-US17210	20020531

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 477209-66-8 REGISTRY
CN L-Leucinamide, N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[(1S)-1-(chloromethyl)-1,6-dihydro-8-(methoxycarbonyl)-7-methyl-5-[[(4-methyl-1-piperazinyl)carbonyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-yl]- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C60 H72 Cl N11 O14
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.







PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 138:4470 CA Full-text
TITLE: Preparation of duocarmycin analogs as potent cytotoxins
INVENTOR(S): Ng, Howard P.; McGee, Danny P. C.; Wu, Guoxian; Li, Zhihong; Gangwar, Sanjeev; Saunders, Oliver L.; Martichonok, Valeri; Astafieva, Irina; Moore, Jimmie; Yarranton, Geoffrey Thomas; King, David J.; Boyd, Sharon; Lobl, Thomas J.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., A Wholly Owned Subsidiary of Corixa Corporation, USA
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096910	A1	20021205	WO 2002-US17210	20020531

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003050331	A1	20030313	US 2002-160972	20020531
US 2003064984	A1	20030403	US 2002-161234	20020531
US 2003073852	A1	20030417	US 2002-161233	20020531
NZ 529788	A	20031219	NZ 2002-529788	20020531
EP 1434778	A1	20040707	EP 2002-731994	20020531

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:

US 2001-295196P	20010531
US 2001-295259P	20010531
US 2001-295342P	20010531
US 2001-304908P	20010711
WO 2002-US17210	20020531

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 477209-63-5 REGISTRY
CN L-Leucinamide, N-[1,4-dioxo-4-(phenylmethoxy)butyl]-β-alanyl-L-leucyl-
L-alanyl-N-[2-[[[2-[[(1S)-1-(chloromethyl)-1,6-dihydro-8-(methoxycarbonyl)-
7-methyl-5-[[(4-methyl-1-piperazinyl)carbonyl]oxy]benzo[1,2-b:4,3-
b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-1H-indol-7-
yl]- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C67 H78 Cl N11 O14
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003050331	A1	20030313	US 2002-160972	20020531
US 2003064984	A1	20030403	US 2002-161234	20020531
US 2003073852	A1	20030417	US 2002-161233	20020531
NZ 529788	A	20031219	NZ 2002-529788	20020531
EP 1434778	A1	20040707	EP 2002-731994	20020531

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:
US 2001-295196P 20010531
US 2001-295259P 20010531
US 2001-295342P 20010531
US 2001-304908P 20010711
WO 2002-US17210 20020531

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 477209-56-6 REGISTRY
CN L-Leucinamide, N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-N-
[2-[[[2-[[(1S)-1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-(methoxycarbonyl)-
7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-
benzofuranyl]amino]carbonyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C54 H61 Cl N8 O14
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

PAGE 1-B



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 138:4470 CA Full-text
TITLE: Preparation of duocarmycin analogs as potent cytotoxins
INVENTOR(S): Ng, Howard P.; McGee, Danny P. C.; Wu, Guoxian; Li, Zhihong; Gangwar, Sanjeev; Saunders, Oliver L.; Martichonok, Valeri; Astafieva, Irina; Moore, Jimmie; Yarranton, Geoffrey Thomas; King, David J.; Boyd, Sharon; Lobl, Thomas J.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., A Wholly Owned Subsidiary of Corixa Corporation, USA
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096910	A1	20021205	WO 2002-US17210	20020531

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 138:4470 CA Full-text
TITLE: Preparation of duocarmycin analogs as potent cytotoxins
INVENTOR(S): Ng, Howard P.; McGee, Danny P. C.; Wu, Guoxian; Li, Zhihong; Gangwar, Sanjeev; Saunders, Oliver L.; Martichonok, Valeri; Astafieva, Irina; Moore, Jimmie; Yarranton, Geoffrey Thomas; King, David J.; Boyd, Sharon; Lobl, Thomas J.

PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., A Wholly Owned Subsidiary of Corixa Corporation, USA
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096910	A1	20021205	WO 2002-US17210	20020531
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003050331	A1	20030313	US 2002-160972	20020531
US 2003064984	A1	20030403	US 2002-161234	20020531
US 2003073852	A1	20030417	US 2002-161233	20020531
NZ 529788	A	20031219	NZ 2002-529788	20020531
EP 1434778	A1	20040707	EP 2002-731994	20020531
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:
US 2001-295196P 20010531
US 2001-295259P 20010531
US 2001-295342P 20010531
US 2001-304908P 20010711
WO 2002-US17210 20020531

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 477209-54-4 REGISTRY
CN L-Leucinamide, N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[(1S)-1-(chloromethyl)-5-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1,6-dihydro-8-(methoxycarbonyl)-7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]-(9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C60 H75 Cl N8 O14 Si
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 138:4470 CA Full-text
TITLE: Preparation of duocarmycin analogs as potent cytotoxins
INVENTOR(S): Ng, Howard P.; McGee, Danny P. C.; Wu, Guoxian; Li, Zhihong; Gangwar, Sanjeev; Saunders, Oliver L.; Martichonok, Valeri; Astafieva, Irina; Moore, Jimmie; Yarranton, Geoffrey Thomas; King, David J.; Boyd, Sharon; Lobl, Thomas J.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., A Wholly Owned Subsidiary of Corixa Corporation, USA
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096910	A1	20021205	WO 2002-US17210	20020531
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003050331	A1	20030313	US 2002-160972	20020531
US 2003064984	A1	20030403	US 2002-161234	20020531
US 2003073852	A1	20030417	US 2002-161233	20020531
NZ 529788	A	20031219	NZ 2002-529788	20020531
EP 1434778	A1	20040707	EP 2002-731994	20020531
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:
US 2001-295196P 20010531
US 2001-295259P 20010531
US 2001-295342P 20010531
US 2001-304908P 20010711
WO 2002-US17210 20020531

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 477209-52-2 REGISTRY
CN L-Leucinamide, N-[1,4-dioxo-4-(phenylmethoxy)butyl]-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[(1S)-1-(chloromethyl)-5-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1,6-dihydro-8-(methoxycarbonyl)-7-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C67 H81 Cl N8 O14 Si
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A





1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 138:4470 CA Full-text
TITLE: Preparation of duocarmycin analogs as potent cytotoxins
INVENTOR(S): Ng, Howard P.; McGee, Danny P. C.; Wu, Guoxian; Li, Zhihong; Gangwar, Sanjeev; Saunders, Oliver L.; Martichonok, Valeri; Astafieva, Irina; Moore, Jimmie; Yarranton, Geoffrey Thomas; King, David J.; Boyd, Sharon; Lobl, Thomas J.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., A Wholly Owned Subsidiary of Corixa Corporation, USA
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096910	A1	20021205	WO 2002-US17210	20020531

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003050331	A1	20030313	US 2002-160972	20020531
US 2003064984	A1	20030403	US 2002-161234	20020531
US 2003073852	A1	20030417	US 2002-161233	20020531
NZ 529788	A	20031219	NZ 2002-529788	20020531
EP 1434778	A1	20040707	EP 2002-731994	20020531

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:	US 2001-295196P	20010531
	US 2001-295259P	20010531
	US 2001-295342P	20010531
	US 2001-304908P	20010711
	WO 2002-US17210	20020531

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 477209-22-6 REGISTRY
CN L-Leucinamide, N-[1,4-dioxo-4-(phenylmethoxy)butyl]-β-alanyl-L-leucyl-L-alanyl-N-[2-[[[2-[[(1S)-1-(chloromethyl)-8-cyano-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-5-benzofuranyl]amino]carbonyl]-5-benzofuranyl]- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C61 H63 Cl N8 O12
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 138:4470 CA Full-text
TITLE: Preparation of duocarmycin analogs as potent cytotoxins
INVENTOR(S): Ng, Howard P.; McGee, Danny P. C.; Wu, Guoxian; Li, Zhihong; Gangwar, Sanjeev; Saunders, Oliver L.; Martichonok, Valeri; Astafieva, Irina; Moore, Jimmie; Yarranton, Geoffrey Thomas; King, David J.; Boyd, Sharon; Lobl, Thomas J.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., A Wholly Owned Subsidiary of Corixa Corporation, USA
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096910	A1	20021205	WO 2002-US17210	20020531

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003050331	A1	20030313	US 2002-160972	20020531
US 2003064984	A1	20030403	US 2002-161234	20020531
US 2003073852	A1	20030417	US 2002-161233	20020531
NZ 529788	A	20031219	NZ 2002-529788	20020531
EP 1434778	A1	20040707	EP 2002-731994	20020531

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:	US 2001-295196P	20010531
	US 2001-295259P	20010531
	US 2001-295342P	20010531
	US 2001-304908P	20010711
	WO 2002-US17210	20020531

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 372491-73-1 REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, monosodium salt, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C49 H65 N5 O18 . Na
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)
CRN (274912-87-7)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



● Na

PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 135:362468 CA Full-text
TITLE: N-succinyl-(β-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity
AUTHOR(S): Fernandez, Anne-Marie; Van derpoorten, Kim; Dasnois, Luc; Lebtahi, Karim; Dubois, Vincent; Lobl, Thomas J.; Gangwar, Sanjeev; Oliyai, Cecilia; Lewis, Evan R.; Shochat, Dan; Trouet, Andre
CORPORATE SOURCE: Laboratory of Cell Biology, Universite Catholique de Louvain, Louvain-la-Neuve, B-1348, Belg.
SOURCE: Journal of Medicinal Chemistry (2001), 44(22), 3750-3753
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274913-07-4 REGISTRY
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C50 H67 N5 O18
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 138:29142 CA Full-text
TITLE: CD10-activated prodrug compounds
INVENTOR(S): Bebbington, Christopher R.; Nieder, Matthew H.; Cardarelli, Pina M.; Gangwar, Sanjeev; Pickford, Lesley B.; Pan, Chin
PATENT ASSIGNEE(S): Medarex, Inc., USA
SOURCE: PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100353	A2	20021219	WO 2002-US21135	20020610
WO 2002100353	A3	20030522		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1404356 A2 20040407 EP 2002-746852 20020611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2004087497 A1 20040506 US 2002-167627 20020611
PRIORITY APPLN. INFO.: US 2001-297596P 20010611
WO 2002-US21135 20020611

REFERENCE 2

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

REFERENCE 3

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611

PRIORITY APPLN. INFO.: US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

L12 ANSWER 11 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274913-06-3 REGISTRY

CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-[(9H-fluoren-9-ylmethoxy)carbonyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C60 H71 N5 O17
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

REFERENCE 2

ACCESSION NUMBER: 135:362468 CA Full-text
TITLE: N-succinyl-(β-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity
AUTHOR(S): Fernandez, Anne-Marie; Van derpoorten, Kim; Dasnois, Luc; Lebtahi, Karim; Dubois, Vincent; Lobl, Thomas J.; Gangwar, Sanjeev; Oliyai, Cecilia; Lewis, Evan R.; Shochat, Dan; Trouet, Andre
CORPORATE SOURCE: Laboratory of Cell Biology, Universite Catholique de Louvain, Louvain-la-Neuve, B-1348, Belg.
SOURCE: Journal of Medicinal Chemistry (2001), 44(22), 3750-3753
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

REFERENCE 3

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,				

SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611

PRIORITY APPLN. INFO.:
US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

L12 ANSWER 12 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274913-05-2 REGISTRY
CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-,
methyl ester (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C24 H42 N4 O8
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar,
Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew
H.; Pickford, Lesley B.; Trouet, Andre; Yarranton,
Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl.
No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

REFERENCE 2

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: Oligopeptide prodrug compounds and process for
preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder,
Matthew H.; Trouet, Andre; Viski, Peter; Yarranton,
Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611

PRIORITY APPLN. INFO.:
US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

L12 ANSWER 13 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274913-04-1 REGISTRY
CN L-Leucine, N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C22 H38 N4 O8
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
study); PRP (Properties); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



3 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 141:289012 CA Full-text
TITLE: Paclitaxel hybrid derivatives with improved properties
for the treatment of cancer
INVENTOR(S): Erhardt, Paul W.; Klis, Weislaw A.; Sarver, Jeffrey G.
PATENT ASSIGNEE(S): The University of Toledo, USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080412	A2	20040923	WO 2004-US7269	20040305

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,

SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG
PRIORITY APPLN. INFO.: US 2003-452649P 20030307

REFERENCE 2

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

REFERENCE 3

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611

PRIORITY APPLN. INFO.:
US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

L12 ANSWER 14 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274913-03-0 REGISTRY
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-[1,4-dioxo-4-(2-propenyloxy)butyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C52 H69 N5 O18
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

REFERENCE 2

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611

PRIORITY APPLN. INFO.:
US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

L12 ANSWER 15 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274913-02-9 REGISTRY
CN Propanoic acid, 2-hydroxy-, compd. with (8S,10S)-10-[[3-[(β-alanyl-L-leucyl-L-alanyl-L-leucyl)amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5,12-Naphthacenedione, 10-[[3-[(β-alanyl-L-leucyl-L-alanyl-L-leucyl)amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-, mono(2-hydroxypropanoate) (salt) (9CI)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C45 H61 N5 O15 . C3 H6 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

CM 1

CRN 177953-52-5
CMF C45 H61 N5 O15

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



CM 2

CRN 50-21-5
CMF C3 H6 O3



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:
US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

REFERENCE 2

ACCESSION NUMBER: 135:362468 CA Full-text
TITLE: N-succinyl-(β-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity
AUTHOR(S): Fernandez, Anne-Marie; Van derpoorten, Kim; Dasnois, Luc; Lebtahi, Karim; Dubois, Vincent; Lobl, Thomas J.; Gangwar, Sanjeev; Oliyai, Cecilia; Lewis, Evan R.; Shochat, Dan; Trouet, Andre
CORPORATE SOURCE: Laboratory of Cell Biology, Universite Catholique de Louvain, Louvain-la-Neuve, B-1348, Belg.
SOURCE: Journal of Medicinal Chemistry (2001), 44(22), 3750-3753
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

REFERENCE 3

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611
PRIORITY APPLN. INFO.:			US 1998-111793P	19981211
			US 1999-119312P	19990208
			WO 1999-US30393	19991210
			US 2000-211887P	20000614
			US 2001-290448P	20010511

L12 ANSWER 16 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274912-96-8 REGISTRY
CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-
(9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C23 H40 N4 O8
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 138:29142 CA Full-text
TITLE: CD10-activated prodrug compounds
INVENTOR(S): Bebbington, Christopher R.; Nieder, Matthew H.; Cardarelli, Pina M.; Gangwar, Sanjeev; Pickford, Lesley B.; Pan, Chin
PATENT ASSIGNEE(S): Medarex, Inc., USA
SOURCE: PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100353	A2	20021219	WO 2002-US21135	20020610
WO 2002100353	A3	20030522		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1404356	A2	20040407	EP 2002-746852	20020611

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 2004087497	A1	20040506	US 2002-167627	20020611
PRIORITY APPLN. INFO.:			US 2001-297596P	20010611
			WO 2002-US21135	20020611

REFERENCE 2

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:			US 1998-111793P	19981211
			US 1999-119312P	19990208
			WO 1999-US30393	19991210
			US 2000-211887P	20000614
			US 2001-290448P	20010511

REFERENCE 3

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611
PRIORITY APPLN. INFO.:			US 1998-111793P	19981211
			US 1999-119312P	19990208
			WO 1999-US30393	19991210
			US 2000-211887P	20000614
			US 2001-290448P	20010511

L12 ANSWER 17 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274912-95-7 REGISTRY
CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-, phenylmethyl ester (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C30 H46 N4 O8
SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611

PRIORITY APPLN. INFO.:
US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

L12 ANSWER 18 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274912-92-4 REGISTRY
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-[(phenylmethoxy)carbonyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C53 H67 N5 O17
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.





2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

REFERENCE 2

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: Oligopeptide prodrug compounds and process for
preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder,
Matthew H.; Trouet, Andre; Viski, Peter; Yarranton,
Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611

PRIORITY APPLN. INFO.: US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

L12 ANSWER 19 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274912-91-3 REGISTRY
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-(diphenylmethyl)-
β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C58 H71 N5 O15
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar,
Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew
H.; Pickford, Lesley B.; Trouet, Andre; Yarranton,
Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl.
No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

REFERENCE 2

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: Oligopeptide prodrug compounds and process for
preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder,
Matthew H.; Trouet, Andre; Viski, Peter; Yarranton,
Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

JP 2003518000	T2	20030603	JP 2000-586378	19991210

AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611
PRIORITY APPLN. INFO.:			US 1998-111793P	19981211
			US 1999-119312P	19990208
			WO 1999-US30393	19991210
			US 2000-211887P	20000614
			US 2001-290448P	20010511

L12 ANSWER 20 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274912-90-2 REGISTRY
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-(triphenylmethyl)-
β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C64 H75 N5 O15
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.





2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER:	137:284323 CA Full-text
TITLE:	Enzyme-cleavable prodrug compounds
INVENTOR(S):	Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S):	Belg.
SOURCE:	U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393. CODEN: USXXCO
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	3
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:		US 1998-111793P	19981211
		US 1999-119312P	19990208
		WO 1999-US30393	19991210
		US 2000-211887P	20000614
		US 2001-290448P	20010511

REFERENCE 2

ACCESSION NUMBER:	133:48878 CA Full-text
TITLE:	Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S):	Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S):	Coulter Pharmaceutical, Inc., USA
SOURCE:	PCT Int. Appl., 125 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	3
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1144011	A2	20011017	EP 1999-967462 19991210
EP 1144011	A3	20020206	

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2003518000	T2	20030603	JP 2000-586378 19991210

AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611
PRIORITY APPLN. INFO.:			US 1998-111793P	19981211
			US 1999-119312P	19990208
			WO 1999-US30393	19991210
			US 2000-211887P	20000614
			US 2001-290448P	20010511

L12 ANSWER 21 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274912-89-9 REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[[N-(4-carboxy-1-oxobutyl)-β-alanyl-L-
leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-
1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C50 H67 N5 O18
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP
(Properties); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.





3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

REFERENCE 3

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1144011 A2 20011017 EP 1999-967462 19991210
EP 1144011 A3 20020206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
JP 2003518000 T2 20030603 JP 2000-586378 19991210
AU 773420 B2 20040527 AU 2000-23733 19991210
US 2002142955 A1 20021003 US 2001-879442 20010611
PRIORITY APPLN. INFO.: US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

L12 ANSWER 22 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274912-88-8 REGISTRY
CN 5,12-Naphthacenedione, 8-acetyl-10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C49 H65 N5 O17
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.





3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

REFERENCE 2

ACCESSION NUMBER: 136:58787 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Nieder, Matthew H.; Dubois, Vincent; Gangwar, Sanjeev; Lobl, Thomas J.; Pickford, Leslie B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Corixa Corporation, USA
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001095945	A2	20011220	WO 2001-US18903	20010611
WO 2001095945	A3	20020815		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1294405	A2	20030326	EP 2001-950291	20010611

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004510703	T2	20040408	JP 2002-510122	20010611

PRIORITY APPLN. INFO.: US 2000-211887P 20000614
US 2001-290448P 20010511
WO 2001-US18903 20010611

REFERENCE 3

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611

PRIORITY APPLN. INFO.: US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

L12 ANSWER 23 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274912-87-7 REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN CPI 0004Na
CN sALAL-Dox
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C49 H65 N5 O18
CI COM
SR CA
LC STN Files: CA, CAPLUS, PROUSDDR, SYNTHLINE, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



PAGE 1-B



7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 140:156884 CA Full-text
TITLE: CD10 Is a Key Enzyme Involved in the Activation of Tumor-activated Peptide Prodrug CPI-0004Na and Novel Analogues: Implications for the Design of Novel Peptide Prodrugs for the Therapy of CD10+ Tumors

AUTHOR(S): Pan, Chin; Cardarelli, Pina M.; Nieder, Matthew H.; Pickford, Lesley B.; Gangwar, Sanjeev; King, David J.; Yarranton, Geoffrey T.; Buckman, Dana; Roscoe, William; Zhou, Fengmin; Salles, Adam; Chen, Tseng-Hui; Horgan, Killian; Wang, Yi-Hong; Nguyen, Thi; Bebbington, Christopher R.
CORPORATE SOURCE: Corixa Corp., South San Francisco, CA, 94080, USA
SOURCE: Cancer Research (2003), 63(17), 5526-5531
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

REFERENCE 2

ACCESSION NUMBER: 138:29142 CA Full-text
TITLE: CD10-activated prodrug compounds
INVENTOR(S): Bebbington, Christopher R.; Nieder, Matthew H.; Cardarelli, Pina M.; Gangwar, Sanjeev; Pickford, Lesley B.; Pan, Chin
PATENT ASSIGNEE(S): Medarex, Inc., USA
SOURCE: PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100353	A2	20021219	WO 2002-US21135	20020610
WO 2002100353	A3	20030522		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1404356	A2	20040407	EP 2002-746852	20020611

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 2004087497	A1	20040506	US 2002-167627	20020611
PRIORITY APPLN. INFO.:			US 2001-297596P	20010611
			WO 2002-US21135	20020611

REFERENCE 3

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:	US 1998-111793P	19981211
	US 1999-119312P	19990208
	WO 1999-US30393	19991210

	US 2000-211887P	20000614
	US 2001-290448P	20010511

REFERENCE 4

ACCESSION NUMBER: 137:241802 CA Full-text
TITLE: CPI-0004Na, a new extracellularly tumor-activated prodrug of Doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity
AUTHOR(S): Dubois, Vincent; Dasnois, Luc; Lebtahi, Karim; Collot, Francoise; Heylen, Nathalie; Havaux, Nathalie; Fernandez, Anne-Marie; Lobl, Thomas J.; Oliyai, Cecilia; Nieder, Matthew; Shochat, Dan; Yarranton, Geoffrey T.; Trouet, Andre
CORPORATE SOURCE: Universite Catholique de Louvain, Laboratory of Cell Biology, Louvain-la-Neuve, B-1348, Belg.
SOURCE: Cancer Research (2002), 62(8), 2327-2331
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

REFERENCE 5

ACCESSION NUMBER: 136:86054 CA Full-text
TITLE: Tripeptide prodrug compounds
INVENTOR(S): Bebbington, Christopher R.; Dubois, Vincent; Gangwar, Sanjeev; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Leslie B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Corixa Corporation, USA
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000263	A2	20020103	WO 2001-US40925	20010611
WO 2002000263	A3	20020815		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1294403	A2	20030326	EP 2001-942249	20010611

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004501875	T2	20040122	JP 2002-505044	20010611
US 2003181359	A1	20030925	US 2002-311519	20021213
PRIORITY APPLN. INFO.:			US 2000-212880P	20000614
			WO 2001-US40925	20010611

REFERENCE 6

ACCESSION NUMBER: 136:58787 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Nieder, Matthew H.; Dubois, Vincent; Gangwar, Sanjeev; Lobl, Thomas J.; Pickford, Leslie B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Corixa Corporation, USA
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001095945	A2	20011220	WO 2001-US18903	20010611
WO 2001095945	A3	20020815		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1294405 A2 20030326 EP 2001-950291 20010611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004510703 T2 20040408 JP 2002-510122 20010611
PRIORITY APPLN. INFO.: US 2000-211887P 20000614
US 2001-290448P 20010511
WO 2001-US18903 20010611

REFERENCE 7

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: Oligopeptide prodrug compounds and process for
preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder,
Matthew H.; Trouet, Andre; Viski, Peter; Yarranton,
Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1144011 A2 20011017 EP 1999-967462 19991210
EP 1144011 A3 20020206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,



PAGE 1-B



4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English

MC, PT,
IE, SI, LT, LV, FI, RO
JP 2003518000 T2 20030603 JP 2000-586378 19991210
AU 773420 B2 20040527 AU 2000-23733 19991210
US 2002142955 A1 20021003 US 2001-879442 20010611
PRIORITY APPLN. INFO.: US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

L12 ANSWER 24 OF 24 REGISTRY COPYRIGHT 2004 ACS on STN
RN 177953-52-5 REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[(β-alanyl-L-leucyl-L-alanyl-L-leucyl)amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-
tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI)
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5,12-Naphthacenedione, 10-[[3-[[N-[N-(N-β-alanyl-L-leucyl)-L-alanyl]-
L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-
tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C45 H61 N5 O15
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC
(Process); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PROC (Process); USES
(Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

REFERENCE 2

ACCESSION NUMBER: 135:116741 CA Full-text
TITLE: Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to vivo doxorubicin and preliminary in vitro and in studies
AUTHOR(S): Trouet, Andre; Passioukov, Alexandre; Van derpoorten, Kim; Fernandez, Anne-Marie; Abarca-Quinones, Jorge; Baurain, Roger; Lobl, Thomas J.; Oliyai, Cecilia; Shochat, Dan; Dubois, Vincent
CORPORATE SOURCE: Laboratory of Cell Biology, Universite Catholique de Louvain, Louvain-la-Neuve, B-1348, Belg.
SOURCE: Cancer Research (2001), 61(7), 2843-2846
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES
AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

REFERENCE 3

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611

PRIORITY APPLN. INFO.:
US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

REFERENCE 4

ACCESSION NUMBER: 125:49345 CA Full-text
TITLE: Compounds, pharmaceutical composition and diagnostic system comprising same, and their use
INVENTOR(S): Trouet, Andre; Baurain, Roger
PATENT ASSIGNEE(S): La Region Wallonne, Belg.; Baurain, Roger
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9605863	A1	19960229	WO 1995-BE76	19950821
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
BE 1008580	A3	19960604	BE 1994-751	19940819
BE 1008581	A3	19960604	BE 1994-752	19940819
CA 2203622	AA	19960229	CA 1995-2203622	19950821
AU 9532486	A1	19960314	AU 1995-32486	19950821
AU 694546	B2	19980723		
EP 769967	A1	19970502	EP 1995-928905	19950821
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10508291	T2	19980818	JP 1995-507662	19950821
NO 9700748	A	19970410	NO 1997-748	19970218
US 5962216	A	19991005	US 1997-793910	19970401
US 6342480	B1	20020129	US 1999-298330	19990423
US 2002160943	A1	20021031	US 2001-12576	20011109

PRIORITY APPLN. INFO.:
BE 1994-751 19940819
BE 1994-752 19940819
WO 1995-BE76 19950821
US 1997-793910 19970401
US 1999-298330 19990423

=> file hcaplus
COST IN U.S. DOLLARS SINCE FILE
TOTAL ENTRY
SESSION
FULL ESTIMATED COST 379.66
379.87

FILE 'HCAPLUS' ENTERED AT 12:32:15 ON 25 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 25 Oct 2004 VOL 141 ISS 18
FILE LAST UPDATED: 24 Oct 2004 (20041024/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l12
L13 13 L12,

=> l13 and pd<20010611
21421302 PD<20010611
(PD<20010611)
L14 5 L13 AND PD<20010611

=> d l14 1-5 ibib abs hitstr

L14 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:755199 HCAPLUS Full-text
DOCUMENT NUMBER: 137:284323
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210 <--
WO 2000033888	A3	20011108		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:
US 1998-111793P P 19981211
US 1999-119312P P 19990208
WO 1999-US30393 A2 19991210
US 2000-211887P P 20000614
US 2001-290448P P 20010511

OTHER SOURCE(S): MARPAT 137:284323

AB The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are methods of designing prodrugs by utilizing TOP-cleavable sequences within the conjugate and methods of treating patients with prodrugs of the invention.

IT 274912-87-7P 274912-88-8P 274912-89-9P
RL: BSU (Biological study, unclassified); PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(thimet oligopeptidase-cleavable prodrug compds.)

RN 274912-87-7 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 274912-88-8 HCAPLUS
CN 5,12-Naphthacenedione, 8-acetyl-10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 274912-89-9 HCAPLUS
CN 5,12-Naphthacenedione, 10-[[3-[[N-(4-carboxy-1-oxobutyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 177953-52-5P 274912-90-2P 274912-91-3P
274912-92-4P 274912-95-7P 274912-96-8P
274913-02-9P 274913-03-0P 274913-04-1P
274913-05-2P 274913-06-3P 274913-07-4P
RL: BSU (Biological study, unclassified); PNU (Preparation, unclassified);
THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(thimet oligopeptidase-cleavable prodrug compds.)

RN 177953-52-5 HCAPLUS
CN 5,12-Naphthacenedione, 10-[[3-[(β-alanyl-L-leucyl-L-alanyl-L-leucyl)amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 274912-90-2 HCAPLUS
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-(triphenylmethyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 274912-91-3 HCAPLUS
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-(diphenylmethyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 274912-92-4 HCAPLUS
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-[(phenylmethoxy)carbonyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 274912-95-7 HCAPLUS
CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 274912-96-8 HCAPLUS
CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 274913-02-9 HCAPLUS
CN Propanoic acid, 2-hydroxy-, compd. with (8S,10S)-10-[[3-[(β-alanyl-L-leucyl-L-alanyl-L-leucyl)amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 177953-52-5
CMF C45 H61 N5 O15

Absolute stereochemistry.



PAGE 1-B



CM 2

CRN 50-21-5
CMF C3 H6 O3



RN 274913-03-0 HCAPLUS
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-[1,4-dioxo-4-(2-propenyloxy)butyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 274913-04-1 HCAPLUS
CN L-Leucine, N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 274913-05-2 HCAPLUS
CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 274913-06-3 HCAPLUS
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-[(9H-fluoren-9-ylmethoxy)carbonyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-A



PAGE 1-B



RN 274913-07-4 HCAPLUS
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B



L14 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:653068 HCAPLUS Full-text
DOCUMENT NUMBER: 135:362468
TITLE: N-succinyl-(β-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity
AUTHOR(S): Fernandez, Anne-Marie; Van derpoorten, Kim; Dasnois, Luc; Lebtahi, Karim; Dubois, Vincent; Lobl, Thomas J.; Gangwar, Sanjeev; Oliyai, Cecilia; Lewis, Evan R.; Shochat, Dan; Trouet, Andre
CORPORATE SOURCE: Laboratory of Cell Biology, Universite Catholique de Louvain, Louvain-la-Neuve, B-1348, Belg.
SOURCE: Journal of Medicinal Chemistry (2001), 44(22), 3750-3753

CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB I.v. administration of N-(β-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin induces an acute toxic reaction, killing animals in a few minutes. This results from its pos. charge at physiol. pH combined with its propensity to form large aggregates in aqueous solns. Neg. charged N-capped versions of N-(β-alanyl-L-leucyl-L-alanyl-L- leucyl)doxorubicin such as the succinyl derivative can be administered by the i.v. route at more than 10 times the LD50 of doxorubicin without inducing the acute toxic reaction, and they are active in vivo.

IT 274913-02-9P 372491-73-1P
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or
effector, except adverse); BSU (Biological study, unclassified); SPN
(Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(N-succinyl-(β-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an
extracellularly tumor-activated prodrug devoid of i.v. acute toxicity)

RN 274913-02-9 HCAPLUS
CN Propanoic acid, 2-hydroxy-, compd. with (8S,10S)-10-[[3-[(β-alanyl-L-
leucyl-L-alanyl-L-leucyl)amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-
1-methoxy-5,12-naphthacenedione (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 177953-52-5
CMF C45 H61 N5 O15

Absolute stereochemistry.

PAGE 1-A



PAGE 1-A



● Na

PAGE 1-B



IT 274913-06-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(N-succinyl-(β-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an
extracellularly tumor-activated prodrug devoid of i.v. acute toxicity)

RN 274913-06-3 HCAPLUS
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-[(9H-fluoren-9-
ylmethoxy)carbonyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B



CM 2

CRN 50-21-5
CMF C3 H6 O3



RN 372491-73-1 HCAPLUS
CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-
leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-
1-methoxy-, monosodium salt, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:295889 HCAPLUS Full-text
DOCUMENT NUMBER: 135:116741
TITLE: Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies
AUTHOR(S): Trouet, Andre; Passioukov, Alexandre; Van derpoorten, Kim; Fernandez, Anne-Marie; Abarca-Quinones, Jorge;

Baurain, Roger; Lobl, Thomas J.; Oliyai, Cecilia;
Shochat, Dan; Dubois, Vincent
CORPORATE SOURCE: Laboratory of Cell Biology, Universite Catholique de
Louvain, Louvain-la-Neuve, B-1348, Belg.
SOURCE: Cancer Research (2001), 61(7), 2843-2846
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Oligopeptidic derivs. of anthracyclines unable to penetrate cells were prepared and screened for their stability in human blood and their reactivation by peptidases secreted by cancer cells. N-β-alanyl-L- leucyl-L-alanyl-L-leucyl-doxorubicin was selected as a new candidate prodrug. The NH2-terminal β-alanine allows a very good blood stability. A two-step activation by peptidases found in conditioned media of cancer cells ultimately yields N-L-leucyl-doxorubicin. In vitro, when MCF-7/6 cancer cells are exposed to the prodrug, they accumulate about 14 times more doxorubicin than MRC-5 normal fibroblasts, whereas when exposed to doxorubicin the uptake is slightly higher in fibroblasts than in MCF-7/6 cells. This increased specificity of the prodrug over doxorubicin was confirmed in cytotoxicity assays using the same cell types. In vivo, the prodrug proved about nine times less toxic than doxorubicin in the normal mouse and also much more efficient in two different exptl. chemotherapy models of human breast tumors.

IT 177953-52-5
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(extracellularly tumor-activated prodrugs for selective chemotherapy of cancer and application to doxorubicin and preliminary in vitro and in vivo studies in relation to toxicity)
RN 177953-52-5 HCAPLUS
CN 5,12-Naphthacenedione, 10-[[3-[(β-alanyl-L-leucyl-L-alanyl-L-leucyl)amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:401690 HCAPLUS Full-text
DOCUMENT NUMBER: 133:48878
TITLE: Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210 <--
WO 2000033888	A3	20011108		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611
PRIORITY APPLN. INFO.:			US 1998-111793P	P 19981211
			US 1999-119312P	P 19990208
			WO 1999-US30393	W 19991210
			US 2000-211887P	P 20000614
			US 2001-290448P	P 20010511

OTHER SOURCE(S): MARPAT 133:48878

AB The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme trouase. Also disclosed are processes for making the prodrug compds.

IT 177953-52-5 274912-87-7 274912-88-8
274912-89-9 274912-90-2 274912-91-3
274912-92-4 274912-95-7 274912-96-8
274913-02-9 274913-03-0 274913-04-1
274913-05-2 274913-06-3 274913-07-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oligopeptide prodrug compds. and process for preparation thereof)
RN 177953-52-5 HCAPLUS
CN 5,12-Naphthacenedione, 10-[[3-[(β-alanyl-L-leucyl-L-alanyl-L-leucyl)amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 274912-87-7 HCAPLUS
CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-
leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-
1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



RN 274912-88-8 HCAPLUS
CN 5,12-Naphthacenedione, 8-acetyl-10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-
alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-
hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-,
(8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



RN 274912-89-9 HCAPLUS
CN 5,12-Naphthacenedione, 10-[[3-[[N-(4-carboxy-1-oxobutyl)-β-alanyl-L-
leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-
1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



RN 274912-90-2 HCAPLUS
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-(triphenylmethyl)-
β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



RN 274912-91-3 HCAPLUS
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-(diphenylmethyl)-
β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 274912-92-4 HCAPLUS
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-[(phenylmethoxy)carbonyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-
α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 274913-02-9 HCAPLUS
CN Propanoic acid, 2-hydroxy-, compd. with (8S,10S)-10-[[3-[(β-alanyl-L-
leucyl-L-alanyl-L-leucyl)amino]-2,3,6-trideoxy-α-L-lyxo-
hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-
1-methoxy-5,12-naphthacenedione (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 177953-52-5
CMF C45 H61 N5 O15

Absolute stereochemistry.

PAGE 1-A



PAGE 1-A



PAGE 1-B



RN 274912-95-7 HCAPLUS
CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-,
phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 274912-96-8 HCAPLUS
CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-

PAGE 1-B



CM 2

CRN 50-21-5
CMF C3 H6 O3

RN 274913-03-0 HCAPLUS
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-[1,4-dioxo-4-(2-
propenyloxy)butyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 274913-04-1 HCAPLUS
CN L-Leucine, N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 274913-05-2 HCAPLUS
CN L-Leucine, N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 274913-06-3 HCAPLUS
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-[(9H-fluoren-9-ylmethoxy)carbonyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 274913-07-4 HCAPLUS
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-(4-methoxy-1,4-dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L14 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1996:377089 HCAPLUS Full-text
DOCUMENT NUMBER: 125:49345
TITLE: Compounds, pharmaceutical composition and diagnostic system comprising same, and their use
INVENTOR(S): Trouet, Andre; Baurain, Roger
PATENT ASSIGNEE(S): La Region Wallonne, Belg.; Baurain, Roger
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9605863	A1	19960229	WO 1995-BE76	19950821 <--
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
BE 1008580	A3	19960604	BE 1994-751	19940819 <--
BE 1008581	A3	19960604	BE 1994-752	19940819 <--
CA 2203622	AA	19960229	CA 1995-2203622	19950821 <--
AU 9532486	A1	19960314	AU 1995-32486	19950821 <--
AU 694546	B2	19980723		
EP 769967	A1	19970502	EP 1995-928905	19950821 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10508291	T2	19980818	JP 1995-507662	19950821 <--
NO 9700748	A	19970410	NO 1997-748	19970218 <--
US 5962216	A	19991005	US 1997-793910	19970401 <--
US 6342480	B1	20020129	US 1999-298330	19990423
US 2002160943	A1	20021031	US 2001-12576	20011109

PRIORITY APPLN. INFO.:

BE 1994-751	A	19940819
BE 1994-752	A	19940819
WO 1995-BE76	W	19950821
US 1997-793910	A1	19970401
US 1999-298330	A1	19990423

OTHER SOURCE(S): MARPAT 125:49345

AB The compds. W-Z-M of the invention comprise an element M, selected from markers and therapeutic agents having an intracellularly active site, linked to a ligand W-Z having an arm Z linked to a terminal group W. The bond between the arm Z of the ligand W-Z and the element M prevents the compound (W-Z-M) from penetrating within the cells and/or inhibits expression of the marker M. This bond is selectively cleaved by factors secreted by target cells so as to enable the marker M to be expressed in the target cells or the therapeutic agent M to penetrate therein; the terminal group W ensures that the compound (W-Z-M) is stable in serum and circulating blood. Data

are presented for e.g. effect of β-Ala-L-Leu-L-Ala-L-Leu-daunorubicin conjugate with mammary carcinoma cells. Also described is characterization of protease(s) secreted into the extracellular medium and able to hydrolyze β-Ala-Leu-Ala-Leu-doxorubicin.

IT 177953-52-5P
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(drug conjugates and marker conjugates with cleavable bond, pharmaceutical compns., and diagnostic system)

RN 177953-52-5 HCAPLUS

CN 5,12-Naphthacenedione, 10-[[3-[(β-alanyl-L-leucyl-L-alanyl-L-leucyl)amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



TOTAL
ENTRY

SESSION
CA SUBSCRIBER PRICE -3.50 -
3.50

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:33:42 ON 25 OCT 2004



=> DIS HIST

(FILE 'HOME' ENTERED AT 12:28:11 ON 25 OCT 2004)

FILE 'REGISTRY' ENTERED AT 12:28:15 ON 25 OCT 2004
L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 0 S L1 SAM
L4 0 S L1 FAM
L5 17 S L1 FUL
L6 1 S L2 SAM
L7 0 S L2 FAM
L8 11 S L2 FUL
L9 13 L5 NOT L8
L10 4 L5 AND L8
L11 7 L8 NOT L10
L12 24 L9 OR L10 OR L11

FILE 'HCAPLUS' ENTERED AT 12:32:15 ON 25 OCT 2004
L13 13 S L12
L14 5 L13 AND PD<20010611

=>

=>
Executing the logoff script...

=> LOG H

COST IN U.S. DOLLARS SINCE FILE
TOTAL
ENTRY

SESSION
FULL ESTIMATED COST 28.52
408.39

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653adk

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HCAPLUS' AT 13:30:12 ON 25 OCT 2004
FILE 'HCAPLUS' ENTERED AT 13:30:12 ON 25 OCT 2004
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE
TOTAL                                                  ENTRY

SESSION
FULL ESTIMATED COST                                    30.88
410.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE
TOTAL                                                  ENTRY

SESSION
CA SUBSCRIBER PRICE                                    -3.50
3.50

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE
TOTAL                                                  ENTRY

SESSION
FULL ESTIMATED COST                                    30.88
410.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE
TOTAL                                                  ENTRY

SESSION
CA SUBSCRIBER PRICE                                    -3.50
3.50

FILE 'REGISTRY' ENTERED AT 13:30:18 ON 25 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   24 OCT 2004  HIGHEST RN 768347-62-2
DICTIONARY FILE UPDATES:  24 OCT 2004  HIGHEST RN 768347-62-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for
details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading H:\STN queries\09879442f.str
```



```
chain nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20
21  22  23  24  25
chain bonds :
1-3  1-2  3-4  3-8  4-5  5-6  5-7  8-9  9-10  9-11  10-20  12-17  12-
13  12-21  13-14  14-15  14-16  17-18  18-19  18-23  20-21  21-22
23-24  24-25
exact/norm bonds :
1-2  3-8  8-9  9-11  10-20  12-17  17-18  18-19  20-21  21-22  24-25
exact bonds :
1-3  3-4  4-5  5-6  5-7  9-10  12-13  12-21  13-14  14-15  14-16  18-
23  23-24

Match level :
1:CLASS  2:CLASS  3:CLASS  4:CLASS  5:CLASS  6:CLASS  7:CLASS
8:CLASS  9:CLASS  10:CLASS  11:CLASS  12:CLASS  13:CLASS  14:CLASS
15:CLASS  16:CLASS  17:CLASS  18:CLASS  19:CLASS  20:CLASS  21:CLASS
22:CLASS  23:CLASS  24:CLASS  25:CLASS


L15     STRUCTURE UPLOADED

=> s l15 sss sam
SAMPLE SEARCH INITIATED 13:30:53 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -   7646 TO ITERATE

 13.1% PROCESSED    1000 ITERATIONS                          0
ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:      147679 TO   158161
PROJECTED ANSWERS:              0 TO        0

L16           0 SEA SSS SAM L15

=> s 15 fam
L17     455990 15

=> s l15 ful
FULL SEARCH INITIATED 13:31:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 153797 TO ITERATE

100.0% PROCESSED  153797 ITERATIONS                         78
ANSWERS
SEARCH TIME: 00.00.03

L18          78 SEA SSS FUL L15

=> d his

     (FILE 'HOME' ENTERED AT 12:28:11 ON 25 OCT 2004)

     FILE 'REGISTRY' ENTERED AT 12:28:15 ON 25 OCT 2004
L1              STRUCTURE UPLOADED
L2              STRUCTURE UPLOADED
L3            0 S L1 SAM
L4            0 S L1 FAM
L5           17 S L1 FUL
L6            1 S L2 SAM
L7            0 S L2 FAM
L8           11 S L2 FUL
L9           13 L5 NOT L8
L10           4 L5 AND L8
L11           7 L8 NOT L10
L12          24 L9 OR L10 OR L11

     FILE 'HCAPLUS' ENTERED AT 12:32:15 ON 25 OCT 2004
L13          13 S L12
L14           5 L13 AND PD<20010611

     FILE 'REGISTRY' ENTERED AT 13:30:18 ON 25 OCT 2004
L15             STRUCTURE UPLOADED
L16           0 S L15 SSS SAM
L17      455990 S 15 FAM
L18          78 S L15 FUL

=> l18 not l12
L19          55 L18 NOT L12

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE
TOTAL                                                  ENTRY

SESSION
FULL ESTIMATED COST                                   160.27
571.02

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE
TOTAL                                                  ENTRY

SESSION
CA SUBSCRIBER PRICE                                    0.00
3.50

FILE 'HCAPLUS' ENTERED AT 13:31:43 ON 25 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in
searching
databases on STN.  Any dissemination, distribution, copying, or
storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 25 Oct 2004  VOL 141 ISS 18
FILE LAST UPDATED: 24 Oct 2004  (20041024/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=> l19
L20          19 L19

=> d his

     (FILE 'HOME' ENTERED AT 12:28:11 ON 25 OCT 2004)

     FILE 'REGISTRY' ENTERED AT 12:28:15 ON 25 OCT 2004
L1              STRUCTURE UPLOADED
L2              STRUCTURE UPLOADED
L3            0 S L1 SAM
L4            0 S L1 FAM
L5           17 S L1 FUL
L6            1 S L2 SAM
L7            0 S L2 FAM
L8           11 S L2 FUL
```

```
L9          13 L5 NOT L8
L10          4 L5 AND L8
L11          7 L8 NOT L10
L12         24 L9 OR L10 OR L11

     FILE 'HCAPLUS' ENTERED AT 12:32:15 ON 25 OCT 2004
L13         13 S L12
L14          5 L13 AND PD<20010611

     FILE 'REGISTRY' ENTERED AT 13:30:18 ON 25 OCT 2004
L15             STRUCTURE UPLOADED
L16          0 S L15 SSS SAM
L17     455990 S 15 FAM
L18         78 S L15 FUL
L19         55 L18 NOT L12

     FILE 'HCAPLUS' ENTERED AT 13:31:43 ON 25 OCT 2004
L20         19 L19

=> s l19
L21         19 L19

=> s l21 and l13
L22          6 L21 AND L13

=> l21 not l21
L23          0 L21 NOT L21

=> l21 not l22
L24         13 L21 NOT L22

=> l24 and pd<20010611
     21421302 PD<20010611
                (PD<20010611)
L25          7 L24 AND PD<20010611

=> l25 not l14
L26          7 L25 NOT L14

=> d l26 ibib hitstr abs

L26  ANSWER 1 OF 7  HCAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2001:818786  HCAPLUS Full-text
DOCUMENT NUMBER:          136:102240
TITLE:                    Highly Enantioselective Enone Epoxidation
Catalyzed by
                          Short Solid Phase-Bound Peptides: Dominant
Role of
                          Peptide Helicity
AUTHOR(S):                Berkessel, Albrecht; Gasch, Norbert;
Glaubitz, Katja;
                          Koch, Christoph
CORPORATE SOURCE:         Institut fuer Organische Chemie,
Universitaet zu
                          Koeln, Cologne, D-50939, Germany
SOURCE:                   Organic Letters (2001), 3(24), 3839-3842
                          CODEN: ORLEF7; ISSN: 1523-7060
```


AB The series of L-Leu 1-20-mers, peptides carrying 1-5 N-terminal Gly residues, and oligomers of (S)-β3-Leu and (1R,2R)-2-aminocyclohexanecarboxylic acid were synthesized on TentaGel S NH2. Five L-Leu residues were found sufficient to catalyze the Julia-Colonna epoxidn. of chalcone with 96-98% ee. Experiment and mol. modeling suggest that catalysis is effected by binding of the enone to the N-terminus, and the helicity of the peptide dets. the epoxide configuration through face-selective delivery of a hydroperoxide anion.


```
REFERENCE COUNT:          21    THERE ARE 21 CITED REFERENCES
AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

=> d l26 ibib hitstr abs 2-7

L26  ANSWER 2 OF 7  HCAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2000:901177  HCAPLUS Full-text
DOCUMENT NUMBER:          134:189718
TITLE:                    A Differential Scanning Calorimetric and 31P
NMR
                          Spectroscopic Study of the Effect of
Transmembrane
                          α-Helical Peptides on the Lamellar-Reversed
                          Hexagonal Phase Transition of
Phosphatidylethanolamine
                          Model Membranes
AUTHOR(S):                Liu, Feng; Lewis, Ruthven N. A. H.; Hodges,
Robert S.;
                          McElhaney, Ronald N.
CORPORATE SOURCE:         Department of Biochemistry, University of
Alberta,
                          Edmonton, AB, T6G 2H7, Can.
SOURCE:                   Biochemistry (2001), 40(3), 760-768
                          CODEN: BICHAW; ISSN: 0006-2960
PUBLISHER:                American Chemical Society
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
IT   327166-44-9
     RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
     study, unclassified); PRP (Properties); BIOL (Biological study)
        (DSC and 31P NMR spectroscopic study of the effect of
transmembrane
        α-helical peptides on the lamellar-reversed hexagonal phase
        transition of phosphatidylethanolamine model membranes)
RN   327166-44-9  HCAPLUS
CN   L-Alaninamide, N-acetyl-3-amino-L-alanyl-3-amino-L-alanyl-L-
leucyl-L-
     leucyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-
leucyl-L-
     leucyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-
leucyl-L-
     leucyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-3-
amino-L-
     alanyl-3-amino- (9CI)  (CA INDEX NAME)

Absolute stereochemistry.

PUBLISHER:                American Chemical Society
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
OTHER SOURCE(S):          CASREACT 136:102240
IT   389057-41-4DP, polymer-supported 389057-42-5DP,
     polymer-supported
     RL: CAT (Catalyst use); SPN (Synthetic preparation); PREP
(Preparation);
     USES (Uses)
        (stereoselective epoxidn. of chalcone catalyzed by polymer-
supported
        leucine oligomers)
RN   389057-41-4  HCAPLUS
CN   L-Leucine, N-[(3S)-3-amino-5-methyl-1-oxohexyl]-L-leucyl-L-
leucyl- (9CI)
     (CA INDEX NAME)

Absolute stereochemistry.
```



```
RN   389057-42-5  HCAPLUS
CN   L-Leucine, N-[(3S)-3-amino-5-methyl-1-oxohexyl]-L-leucyl-L-
leucyl-L-leucyl-
       (9CI)  (CA INDEX NAME)

Absolute stereochemistry.
```



PAGE 1-A



PAGE 1-B



PAGE 2-B



PAGE 2-C



PAGE 2-D

—NH2

AB We have investigated the effects of the model α-helical transmembrane peptide Ac-K2L24K2-amide (L24) on the thermotropic phase behavior of aqueous dispersions of 1,2-dielaidoylphosphatidylethanolamine (DEPE) to understand better the interactions between lipid bilayers and the membrane-spanning segments of integral membrane proteins. We studied in particular the effect of L24 and three derivs. thereof on the liquid-crystalline lamellar (Lα)-reversed hexagonal (HII) phase transition of DEPE model membranes by differential scanning calorimetry and 31P NMR spectroscopy. We found that the incorporation of L24 progressively decreases the temperature, enthalpy, and cooperativity of the Lα-HII phase transition, as well as induces the formation of an inverted cubic phase, indicating that this transmembrane peptide promotes the formation of inverted non-lamellar phases, despite the fact that the hydrophobic length of this peptide exceeds the hydrophobic thickness of the host lipid bilayer. These characteristic effects are not altered by truncation of the side chains of the terminal lysine residues or by replacing each of the leucine residues at the end of the polyleucine core of L24 with a tryptophan residue. Thus, the characteristic effects of these transmembrane peptides on DEPE thermotropic phase behavior are independent of their detailed chemical structure. Importantly, significantly shortening the polyleucine core of L24 results in a smaller decrease in the Lα-HII phase transition temperature of the DEPE matrix into which it is incorporated, and reducing the thickness of the host phosphatidylethanolamine bilayer results in a larger reduction in the Lα-HII phase transition temperature These results are not those predicted by hydrophobic mismatch considerations or reported in previous studies of other transmembrane α-helical peptides containing a core of an alternating sequence of leucine and alanine residues. We thus conclude that the hydrophobicity and conformational flexibility of transmembrane peptides can affect their propensity to induce the formation of inverted non-lamellar phases by mechanisms not primarily dependent on lipid-peptide hydrophobic mismatch.

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:842160 HCAPLUS Full-text
DOCUMENT NUMBER: 134:5165
TITLE: Minimal isolation peptide synthesis process using ion-exchange resins as scavenging agents
INVENTOR(S): Tolle, John C.; Califano, Jean-Christophe; Dhaon, Madhup K.; Sachs, Howard A.; Blodgett, James K.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000071569	A1	20001130	WO 2000-US14152	20000523 <--
W: CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1180115	A1	20020220	EP 2000-936209	20000523
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2003500415	T2	20030107	JP 2000-619824	20000523
PRIORITY APPLN. INFO.:			US 1999-322762	A 19990526
			US 2000-528899	A 20000320
			WO 2000-US14152	W 20000523

IT 308812-43-3P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(liquid-phase peptide synthesis using minimal isolation and ion-exchange resins as scavenging agents)
RN 308812-43-3 HCAPLUS
CN L-Leucine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-β-alanyl-L-leucyl-L-alanyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB A process for the prodn. of a polypeptide having a pre-detd. no. and sequence of amino acid residues comprises: (1) exposing a first substrate amino acid or peptide fragment to a stoichiometric excess of a second reactant amino acid or peptide fragment to form a condensation product, (2) contacting the reaction solution from the first step with an insol. scavenger to sequester the excess of the second reactant amino acid or peptide fragment, (3) removing from the solution the sequestered excess second reactant amino acid or peptide fragment, (4) subjecting the reaction solution to a reaction which removes the protecting group from either the N- or C-terminus of the condensation product of the first step, and (5) if necessary, repeating the first through fourth steps. The method is capable of large-scale production of peptides in solution, is not subject to the one-terminus-only limitation of the solid-phase method, possesses the "cleanliness" of the solid-phase method and, like the solid-phase method, is capable of automation. Most importantly, however, the method of the present invention does not require the frequent isolation of intermediates in a lengthy synthetic sequence nor, necessarily, the removal of all contaminating byproducts from the reaction mixture prior to subsequent processing steps. The method was applied to the synthesis of Z-Lys(Boc)-Ala-Phe-Val-Lys(Boc)-Ile-Leu-Lys(Boc)-Lys(Boc)-OMe (Z = benzyloxycarbonyl, Boc = tert-butoxycarbonyl), Z-Lys(Boc)-Phe-Leu- Lys(Boc)-Lys(Boc)-Ala-Lys(Boc)-Lys(Boc)-Phe-Gly-OMe, and Fmoc-β-Ala-Leu-Ala-Leu-OBu-t (Fmoc = 9-fluorenylmethoxycarbonyl).

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:724187 HCAPLUS Full-text
DOCUMENT NUMBER: 126:4221
TITLE: Method of photochemical immobilization of ligands using quinones
INVENTOR(S): Jacobsen, Mogens Havsteen; Koch, Troels
PATENT ASSIGNEE(S): Jacobsen, Mogens, Havsteen, Den.
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9631557	A1	19961010	WO 1996-DK167	19960403 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
CA 2217053	AA	19961010	CA 1996-2217053	19960403 <--

AU 9653329 A1 19961023 AU 1996-53329
19960403 <--
AU 699321 B2 19981203
EP 820483 A1 19980128 EP 1996-909990
19960403 <--
EP 820483 B1 20001213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI
JP 11505554 T2 19990521 JP 1996-529895
19960403 <--
JP 3124037 B2 20010115
AT 198079 E 20001215 AT 1996-909990
19960403 <--
ES 2153097 T3 20010216 ES 1996-909990
19960403 <--
PT 820483 T 20010330 PT 1996-909990
19960403 <--
US 6033784 A 20000307 US 1997-930623
19971007 <--
GR 3035079 T3 20010330 GR 2000-402602
20001214 <--
PRIORITY APPLN. INFO.: DK 1995-425 A
19950407
WO 1996-DK167 W
19960403
OTHER SOURCE(S): CASREACT 126:4221; MARPAT 126:4221
IT 183808-44-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(photochem. immobilization of ligands using quinones)
RN 183808-44-8 HCAPLUS
CN L-Histidine, N-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-β-alanyl-L-leucyl-L-lysyl-L-leucyl-L-lysyl-L-tryptophyl-L-lysyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl-L-histidyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



AB A method is disclosed for immobilizing a ligand on the surface of a carbon-containing substrate material, said method comprising a photochem. step of linking ≥1 photochem. reactive compds. to a carbon-containing material surface, wherein the photochem. reactive compound is a quinone compound containing a cyclic hydrocarbon or 2-10 fused cyclic hydrocarbons, with at least 2 conjugated carbonyl groups, and wherein the photochem. step comprises irradiation of the photochem. reactive compound with nonionizing electromagnetic radiation having a wavelength in the range from UV to visible light. The products of this invention can be used as, e.g., carriers for solid-phase immunoassays.

L26 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:860771 HCAPLUS Full-text
DOCUMENT NUMBER: 124:56674
TITLE: Super-secondary structure with amphiphilic β-strands probed by pyrenylalanine
AUTHOR(S): Ono, Shin; Kameda, Naoyoshi; Yoshimura, Toshiaki;
Mihara, Hisakazu; Nishino, Norikazu
CORPORATE SOURCE: Dep. Chemical and Biochemical Engineering, Toyama Univ., Gofuku, 930, Japan
SOURCE: Chemistry Letters (1995), (10), 965-6
CODEN: CMLTAG; ISSN: 0366-7022
PUBLISHER: Nippon Kagakkai
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 159922-47-1P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(super-secondary structure with amphiphilic β-strands probed by pyrenylalanine)
RN 159922-47-1 HCAPLUS
CN L-Alaninamide, 1,1'-([2,2'-bipyridine]-4,4'-diyldicarbonyl)bis[β-alanyl-L-leucyl-L-lysyl-L-leucyl-L-alanyl-3-(1-pyrenyl)-L-alanyl-L-lysyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-leucyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-C



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-A



AB A peptide composed of two amphiphilic β-strands was designed and synthesized. The CD and fluorescence spectra of L-1-pyrenylalanine introduced in each segment probed that a super-secondary structure with two β-strands was formed with a left-banded twist and transformed to α-helixes by the addition of trifluoroethanol.

L26 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:435168 HCAPLUS Full-text
DOCUMENT NUMBER: 123:56544
TITLE: The Arndt-Eistert reaction in peptide chemistry: a facile access to homopeptides
AUTHOR(S): Podlech, Joachim; Seebach, Dieter
CORPORATE SOURCE: Lab. Org. Chem., Eidgenoessischen Technischen Hochschule, Zurich, CH-8092, Switz.
SOURCE: Angewandte Chemie, International Edition in English (1995), 34(4), 471-2
CODEN: ACIEAY; ISSN: 0570-0833
PUBLISHER: VCH
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 123:56544
IT 164402-23-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(Arndt-Eistert homologation and peptide coupling in preparation of homopeptides)
RN 164402-23-7 HCAPLUS
CN L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl-N-methylglycyl-5-methyl-(S)-3-aminohexanoyl-L-leucyl-N-methylglycyl-, methyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



GI



II

AB Treatment of N-protected amino acids and peptides R1NHCHR2CO2H [R1 = PhCH2O2C (Z), Z-Ala, Me3CO2C-Leu-Sar; R2 = Me, CH2CHMe2] with ClCO2Et/Et3N, followed by CH2N2 gave diazoketones R1NHCHR2COCHN2 (I) in 41-86% yields. Treatment of the diazoketones with amino acid or peptide esters H-R3 (R3 = Val-OCH2Ph, Sar-MeLeu-OCH2Ph, Sar-Leu-OMe) in the presence of silver benzoate gave homopeptides R1NHCHR2CH2COR3 in 60-95% yields. Treatment of diazoketone I (R = Z-Ala) with silver benzoate in MeOH gave the expected homologated ester Z-Ala-NHCHMeCH2CO2Me, while treatment with silver benzoate in THF in the absence of a nucleophile gave dihydrooxzinone II.

L26 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:16051 HCAPLUS Full-text
DOCUMENT NUMBER: 122:56489
TITLE: Evaluation of the structure of β turn β type polypeptide with 1-pyrenylalanine as CD and fluorescent probe
AUTHOR(S): Ono, Shin; Kameda, Naoyoshi; Fujii, Ritsuko; Yoshimura, Toshiaki; Shimasaki, Choichiro; Tsukurimichi, Eiichi; Mihara, Hisakazu; Nishino, Norikazu
CORPORATE SOURCE: Fac. Eng., Toyama Univ., Gofuku, 930, Japan
SOURCE: Peptide Chemistry (1993), 31st, 449-52
CODEN: PECHDP; ISSN: 0388-3698
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 159922-47-1
RL: PRP (Properties)
(evaluation of the structure of β turn β type polypeptide with 1-pyrenylalanine as CD and fluorescent probe)
RN 159922-47-1 HCAPLUS
CN L-Alaninamide, 1,1'-([2,2'-bipyridine]-4,4'-diyldicarbonyl)bis[β-alanyl-L-leucyl-L-lysyl-L-leucyl-L-alanyl-3-(1-pyrenyl)-L-alanyl-L-lysyl-L-leucyl-L-alanyl-L-leucyl-L-lysyl-L-leucyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-C



PAGE 2-A



PAGE 2-B



PAGE 2-C





GI



I

?=



AB A symposium report on the evaluation of the structure of β turn β type polypeptide I with 1-pyrenylalanine as CD and fluorescent probe.

=> DIS HIST

(FILE 'HOME' ENTERED AT 12:28:11 ON 25 OCT 2004)

FILE 'REGISTRY' ENTERED AT 12:28:15 ON 25 OCT 2004
L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 0 S L1 SAM
L4 0 S L1 FAM
L5 17 S L1 FUL
L6 1 S L2 SAM
L7 0 S L2 FAM
L8 11 S L2 FUL
L9 13 L5 NOT L8
L10 4 L5 AND L8
L11 7 L8 NOT L10
L12 24 L9 OR L10 OR L11

FILE 'HCAPLUS' ENTERED AT 12:32:15 ON 25 OCT 2004
L13 13 S L12
L14 5 L13 AND PD<20010611

FILE 'REGISTRY' ENTERED AT 13:30:18 ON 25 OCT 2004
L15 STRUCTURE UPLOADED
L16 0 S L15 SSS SAM
L17 455990 S 15 FAM
L18 78 S L15 FUL
L19 55 L18 NOT L12

FILE 'HCAPLUS' ENTERED AT 13:31:43 ON 25 OCT 2004
L20 19 L19
L21 19 S L19
L22 6 S L21 AND L13
L23 0 L21 NOT L21
L24 13 L21 NOT L22
L25 7 L24 AND PD<20010611
L26 7 L25 NOT L14

=>

=>
Executing the logoff script...

=> LOG H

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL
SESSION		
FULL ESTIMATED COST	40.40	611.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL
SESSION		
CA SUBSCRIBER PRICE	-4.90	8.40

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:33:31 ON 25 OCT 2004

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653adk

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HCAPLUS' AT 14:25:58 ON 25 OCT 2004
FILE 'HCAPLUS' ENTERED AT 14:25:58 ON 25 OCT 2004
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE TOTAL
	ENTRY
SESSION	
FULL ESTIMATED COST	40.40 611.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE TOTAL
	ENTRY
SESSION	
CA SUBSCRIBER PRICE	-4.90 8.40

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE TOTAL
	ENTRY
SESSION	
FULL ESTIMATED COST	40.40 611.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE TOTAL
	ENTRY
SESSION	
CA SUBSCRIBER PRICE	-4.90 8.40

FILE 'REGISTRY' ENTERED AT 14:26:04 ON 25 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 OCT 2004 HIGHEST RN 768347-62-2
DICTIONARY FILE UPDATES: 24 OCT 2004 HIGHEST RN 768347-62-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading H:\STN queries\09879442g.str



chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-3 1-2 3-4 4-5 5-6 6-7 6-8 8-9 9-10 10-11 10-12
exact/norm bonds :
1-2 4-5 5-6 6-7 10-11 10-12
exact bonds :
1-3 3-4 6-8 8-9 9-10

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS
8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS

L27 STRUCTURE UPLOADED

=> s l27 sam
SAMPLE SEARCH INITIATED 14:26:17 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 23816 TO ITERATE

4.2% PROCESSED 1000 ITERATIONS 48
ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 467091 TO 485549
PROJECTED ANSWERS: 20835 TO 24891

L28 48 SEA SSS SAM L27

=> d l28 1-3 ide ibib

L28 ANSWER 1 OF 48 REGISTRY COPYRIGHT 2004 ACS on STN
RN 749239-57-4 REGISTRY
CN L-Asparagine, L-arginyl-L-arginyl-L-tyrosyl-L-lysyl-L-lysyl-L-lysyl-L-
glutaminyl-L-valyl-L-α-aspartyl-L-α-glutamyl-L-glutaminyl-L-methionyl-L-arginyl-L-α-aspartyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4697: PN: WO2004072263 PAGE: 174 claimed protein
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C82 H140 N30 O26 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PRP (Properties)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 3-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER:	141:237763 CA Full-text
TITLE:	Protein 158P1D7 as a marker and target for the diagnosis and treatment of bladder, prostate, colon, lung, breast, cervical and ovarian cancer
INVENTOR(S):	Jakobovits, Aya; Morrison, Robert Kendall; Raitano, Arthur B.; Challita-Eid, Pia M.; Perez-Villar, Juan J.; Meyrick Morrison, Karen Jane; Faris, Mary; Ge, Wangmao; Gudas, Jean; Kanner, Steven B.
PATENT ASSIGNEE(S):	Agensys, Inc., USA; et al.

SOURCE: PCT Int. Appl., 290 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004072263	A2	20040826	WO 2004-US3984	20040210

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-446633P 20030210

L28 ANSWER 2 OF 48 REGISTRY COPYRIGHT 2004 ACS on STN
RN 741262-40-8 REGISTRY
CN L-Lysine, L-glutaminyl-L-alanyl-L-α-glutamyl-L-leucyl-L-α-asparty l-L-asparaginyl-L-lysyl-L-tyrosyl-L-alanylglycyl-L-lysylglycyl-L-tyrosyl-L-lysyl-L-leucylglycyl-L-seryl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5: PN: WO2004069163 SEQID: 5 claimed sequence
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C87 H140 N24 O28
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 141:205666 CA Full-text
TITLE: Cloning, sequencing and serotype analysis of cross-protective CopB protein epitopes of Moraxella catarrhalis and use in immunization
INVENTOR(S): Liu, Dai-Fang; Mcmichael, John Calhoun; Baker, Steven Morris; Fletcher, Leah Diane
PATENT ASSIGNEE(S): Wyeth Holdings Corporation, USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069163	A2	20040819	WO 2004-US2383	20040127

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-443600P 20030130

L28 ANSWER 3 OF 48 REGISTRY COPYRIGHT 2004 ACS on STN
RN 721941-88-4 REGISTRY
CN L-Serine, glycyl-L-threonyl-L-α-aspartyl-L-asparaginyl-L-seryl-L-tryptophyl-L-leucyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1299: PN: WO2004058807 SEQID: 1299 unclaimed sequence
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C37 H54 N10 O15
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Patent
RL.P Roles from patents: PRP (Properties)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 141:122325 CA Full-text
TITLE: MHC class I restricted T-cell stimulating peptides for diagnosis and therapy of hepatitis B virus infection
INVENTOR(S): Lasters, Ignace; Desmet, Johan; Stegmann, Toon; Castelein, Bernard
PATENT ASSIGNEE(S): Algonomics N.V., Belg.
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004058807	A2	20040715	WO 2003-EP13948	20031209
WO 2004058807	A3	20040930		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2002-447276 20021224

=> file hcaplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY
SESSION
FULL ESTIMATED COST 8.76
620.18

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY
SESSION
CA SUBSCRIBER PRICE 0.00 -
8.40

FILE 'HCAPLUS' ENTERED AT 14:26:57 ON 25 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 25 Oct 2004 VOL 141 ISS 18
FILE LAST UPDATED: 24 Oct 2004 (20041024/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l28
L29 93 L28

=> d his l27-

(FILE 'HCAPLUS' ENTERED AT 13:31:43 ON 25 OCT 2004)

FILE 'REGISTRY' ENTERED AT 14:26:04 ON 25 OCT 2004
L27 STRUCTURE UPLOADED
L28 48 S L27 SAM

FILE 'HCAPLUS' ENTERED AT 14:26:57 ON 25 OCT 2004
L29 93 S L28

=> l29 and pd<20010611
21421302 PD<20010611
(PD<20010611)
L30 39 L29 AND PD<20010611

=> l30 and py=1996
850467 PY=1996
L31 2 L30 AND PY=1996

=> d l31 1-2 ibib hitstr abs

L31 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:622336 HCAPLUS Full-text
DOCUMENT NUMBER: 127:288307
TITLE: Comparison of cyclic and linear analogs of vasoactive intestinal peptide
AUTHOR(S): Bolin, David R.; Cottrell, Jeanine; Garippa, Ralph; Rinaldi, Nancy; Senda, Ryuko; Simko, Beverly; O'donnell, Margaret
CORPORATE SOURCE: Roche Research Center, Hoffmann-La Roche, Inc., Nutley, NJ, 07110, USA
SOURCE: Drug Design and Discovery (1996), 13(3-4), 107-114
CODEN: DDDIEV; ISSN: 1055-9612
PUBLISHER: Harwood
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 136449-35-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(vasoactive intestinal peptide cyclic and linear analog biol. activity)
RN 136449-35-9 HCAPLUS
CN Vasoactive intestinal octacosapeptide (swine), 1-(N-acetyl-N-methyl-L-alanine)-12-L-lysine-17-L-norleucine-19-L-alanine-26-L-valine-28-L-threoninamide- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







PAGE 2-A



PAGE 2-B

PAGE 2-C



AB A series of i → i + 4 side-chain to side-chain lactam analogs of vasoactive intestinal peptide has been prepared in order to study the effect of cyclization on biol. activity. In vitro, on guinea pig tracheal smooth muscle and on human bronchial tissue, approx. half of the cyclic analogs showed increased potency and half were decreased over the linear analogs. Several cyclic compds. were between 10- and 20-fold more potent and one was 290-fold more potent than the linear species. In vivo, in guinea pigs, the cyclic compds. showed increased potency by up to 70-fold and significantly enhanced duration of action as compared to linear compds.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:168534 HCAPLUS Full-text

DOCUMENT NUMBER: 126:153178

TITLE: Single-chain analogs of the TGF-β superfamily (morphons) prepared as fusion products human protein domains and their therapeutic uses

INVENTOR(S): Keck, Peter C.; Smart, John E.

PATENT ASSIGNEE(S): Creative Biomolecules, Inc., USA

SOURCE: PCT Int. Appl., 132 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640771	A1	19961219	WO 1996-US9293	19960606 <--
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6040431	A	20000321	US 1995-478097	19950607 <--
CA 2223292	AA	19961219	CA 1996-2223292	19960606 <--
AU 9661570	A1	19961230	AU 1996-61570	19960606 <--
AU 717811	B2	20000330		
EP 833844	A1	19980408	EP 1996-919162	19960606 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11510686	T2	19990921	JP 1996-501647	19960606 <--
US 6479643	B1	20021112	US 2000-496398	20000202
AU 770494	B2	20040226	AU 2000-43748	20000629
US 2003176667	A1	20030918	US 2002-187394	20020628

PRIORITY APPLN. INFO.:

US 1995-478097 A 19950607

AU 1996-61570 A3 19960606

WO 1996-US9293 W 19960606

US 2000-496398 A1 20000202

IT 186378-32-5DP, fusion products
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; single-chain analogs of TGF-β superfamily (morphons) prepared as fusion products human protein domains and their therapeutic uses)

RN 186378-32-5 HCAPLUS

CN L-Alanine, L-alanyl-L-prolyl-L-threonyl-L-glutaminyl-L-leucyl-L-asparaginyl-L-alanyl-L-isoleucyl-L-seryl-L-valyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-α-aspartyl-L-α-aspartyl-L-seryl-L-seryl-L-asparaginyl-L-valyl-L-isoleucyl-L-leucyl-L-lysyl-L-lysyl-L-tyrosyl-L-arginyl-L-asparaginyl-L-methionyl-L-valyl-L-valyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D





AB Disclosed is a family of single-chain polypeptide constructs designed to agonize or mimic members of the TGF-β superfamily by binding to a cell surface receptor complementary to the superfamily member. The single-chain constructs of the invention called "morphons" contain in a single biol. active subunit interacting finger and heel regions which together define a tertiary protein structure complementary to the ligand binding surface of a receptor that binds a TGF-β superfamily member. Also disclosed are truncated versions of the morphon constructs. Methods are disclosed for making and using single-chain morphons that have binding affinity for predetd. receptors of the TGF-β superfamily.

=> l30 and succinyl
5205 SUCCINYL
1 SUCCINYLS
5205 SUCCINYL
(SUCCINYL OR SUCCINYLS)
L32 0 L30 AND SUCCINYL

=> s succinyl
5205 SUCCINYL
1 SUCCINYLS
L33 5205 SUCCINYL
(SUCCINYL OR SUCCINYLS)

=> l33 and peptide
318054 PEPTIDE
232501 PEPTIDES
407114 PEPTIDE
(PEPTIDE OR PEPTIDES)
L34 573 L33 AND PEPTIDE

=> l34 and protect?
520390 PROTECT?
L35 64 L34 AND PROTECT?

=> d l35 1-3 ibib

L35 ANSWER 1 OF 64 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:223904 HCAPLUS Full-text
TITLE: Polyethylene glycol-polyamidoamine dendritic micelle as a matrix for substrate protection against alpha-chymotrypsin-catalyzed hydrolysis
AUTHOR(S): Yang, Hu; Lopina, Stephanie T.
CORPORATE SOURCE: Department of Chemical Engineering and Biomedical Engineering, The University of Akron, Akron, OH, 44325, USA
SOURCE: Abstracts of Papers, 227th ACS National Meeting, Anaheim, CA, United States, March 28-April 1, 2004 (2004), COLL-301. American Chemical Society: Washington, D. C.
CODEN: 69FGKM
DOCUMENT TYPE: Conference; Meeting Abstract
LANGUAGE: English

L35 ANSWER 2 OF 64 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:792475 HCAPLUS Full-text
DOCUMENT NUMBER: 139:360752
TITLE: Extended Substrate Specificity of Rat Mast Cell Protease 5, a Rodent α-Chymase with Elastase-like Primary Specificity
AUTHOR(S): Karlson, Ulrika; Pejler, Gunnar; Tomasini-Johansson, Bianca; Hellman, Lars
CORPORATE SOURCE: Department of Cell and Molecular Biology, The Biomedical Center, Uppsala University, Uppsala, SE-751 24, Swed.
SOURCE: Journal of Biological Chemistry (2003), 278(41), 39625-39631
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES
AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 3 OF 64 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:545682 HCAPLUS Full-text
DOCUMENT NUMBER: 139:97659
TITLE: Intramolecularly-quenched near infrared fluorescent probes for tumor imaging
INVENTOR(S): Weissleder, Ralph; Tung, Ching-Hsuan; Mahmood, Umar; Josephson, Lee; Bogdanov, Alexei
PATENT ASSIGNEE(S): The General Hospital Corporation, USA
SOURCE: U.S., 21 pp., Cont.-in-part of U.S. Ser. No. 79,447.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6592847	B1	20030715	US 2000-604145	20000627
US 6083486	A	20000704	US 1998-79447	19980514
WO 2002000265	A1	20020103	WO 2001-US19941	20010622

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2003219383	A1	20031127	US 2003-360890	20030207

PRIORITY APPLN. INFO.: US 1998-79447 A2 19980514
US 2000-604145 A2 20000627
REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES
AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> index biosci
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS	SINCE FILE TOTAL
	ENTRY
SESSION	
FULL ESTIMATED COST	22.14 642.32
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE TOTAL
	ENTRY
SESSION	
CA SUBSCRIBER PRICE	-1.40 - 9.80

=> FIL HOME

COST IN U.S. DOLLARS	SINCE FILE TOTAL
	ENTRY
SESSION	
FULL ESTIMATED COST	30.47 675.07
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE TOTAL
	ENTRY
SESSION	
CA SUBSCRIBER PRICE	0.00 - 9.80

FILE 'HOME' ENTERED AT 14:35:54 ON 25 OCT 2004

=>